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Abstract 
Objectives: Rheumatoid Arthritis (RA) is not commonly associated with central nervous 
system and brain changes. However a number of studies have reported high rates of cognitive 
impairment (CI) in adults with RA. The objective of this systematic review was to identify 
and explore the rates and types of CI in RA.  
Methods: Multiple databases were searched including a time frame between 1994 to 2016 to 
identify studies that have included: (i) adults with RA; (ii) standardized neuropsychological 
tests; and (iii) sufficient information to ascertain the relationship between CI and 
demographic, clinical and psychology factors. Of 1,980 titles, 75 were retained at abstract 
level, 36 at full-text level and 15 studies in the final review. These were evaluated using a 
modified Newcastle-Ottawa Evaluation Scale and the findings were synthesized using a 
narrative approach.  
Results: Ten out of 15 studies compared RA to other clinical and/or control groups. Based on 
summed effect size analyses, individuals with RA significantly under-performed on cognitive 
function tests compared to the control groups; particularly on verbal function, memory, and 
attention. Less clear differences were found between RA and other clinical groups. Some 
demographic (age, education), clinical (disease activity) and psychological (depression) 
factors were associated with CI but inconsistently so across studies. A number of limitations 
were identified: small and predominantly female samples, limited cognitive domain 
inclusion, lack of study details, and management of confounding variables. 
Conclusions: There is evidence of CI in adults with RA. Further studies are required to 
confirm prevalence rates and examine potential mechanisms. 
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Significance and innovations   
¥ Individuals with RA significantly underperform on cognitive function tests. 
¥ Mechanisms of the association between RA and cognitive impairment are unclear. 
¥ Age, education, disease activity and depression appear to be associated with cognitive 
impairment.  
¥ Further research is required to confirm the rates and types of cognitive impairment in 
RA. 
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Rheumatoid arthritis (RA) is the most common chronic inflammatory arthritis. It 
affects between 0.5 and 1% of the population and is more common in women and older 
adults [1, 2]. RA is a multisystem connective tissue disorder with common presentation 
including swollen, painful joints, fatigue and physical disability [3] with structural damage, 
systemic consequences [4] and depression [2]. 
 Neuropsychological impairment is not usually associated with RA. However recent 
studies suggest there may be a link between RA and cognitive impairment and that even mild 
cognitive impairment (CI) can disrupt daily function for individuals with RA [5]. While some 
studies have found a link between RA and CI Ð specifically AlzheimerÕs disease and other 
dementias [6] Ð others have found no such link [7]. A large longitudinal population-based 
study found those with a history of RA were significantly more likely than those with other 
joint diseases to have developed CI over a period of 21 years [8]. The authors suggested the 
link between RA and cognitive decline might be due to inflammation within the brain. 
Further a high risk of cardiovascular comorbidity for patients with RA may also be 
implicated in CI, through mechanisms related to the metabolic syndrome and inflammatory 
proteins [6]. !
 The pathogenic mechanisms of cognitive decline in RA are unknown [4]. It is 
possible that cognitive impairment may be associated with clinical features (e.g. pain, fatigue 
and sleep disturbance Ð as evidenced by research in chronic pain populations) [9] or 
psychological comorbidities (depression, anxiety) [10, 11, 12, 13] but the findings are 
inconsistent. Pain is known to impact cognition Ð particularly memory, mental flexibility and 
attention. This is due in part to the attention-occupying nature of chronic pain and possibly to 
the overlap between the brain regions that involve both pain and cognition [14]. Similarly 
depression can lead to reduced concentration [15] and executive function [16]. There are high 
levels of depression in RA [17] and CI may be a feature of depression.   
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 RA is treated with a range of immunosuppressant agents that can lead to neurotoxicity 
when used long-term [18]. A commonly prescribed medication for RA is Methotrexate 
(MTX), which is highly effective [19] but might be associated with CI [20], mood changes 
and confusion [21]. Glucocorticoid therapy has been associated with an immediate impact on 
memory [22] and a possible cumulative influence on hippocampal function [23]. While there 
seems to be an association between glucocorticoid medication and CI in RA [24] the nature 
of that association remains undetermined.  
 Cognitive function encompasses a range of neuropsychological domains, including: 
orientation; attention/concentration; judgment/problem solving; memory; and verbal and 
visual/spatial function [25]. Impaired cognitive function may influence activities of daily life. 
In the context of RA it may also impact on treatment compliance and effectiveness and 
overall self-care [26, 27]. It follows that cognitive function may form an important indicator 
for assessment and monitoring as part of the overall management of RA.  
 Recent studies have suggested a substantial proportion of adults with RA may have CI 
but the prevalence rates, specific cognitive domains of impairment and clinical significance 
of such impairment are yet to be comprehensively determined.  
 This systematic literature review examined the rates and types of CI in adults with RA 
and set the following research questions: 
1. What are the rates and types of CI among adults with RA? 
2. Which demographic, clinical and psychological factors may be associated with CI in 
adults with RA? 
 In order to synthesize and evaluate findings, this systematic review included peer-
reviewed studies based on formal observer-rated neuropsychological assessments. These are 
the Ôgold standardÕ for assessing cognitive function. 
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Materials and Methods 
 
 This systematic review comprised five stages. Stage One involved a systematic search 
of the literature based on a combination of key words (Stage One: Database search) 
conducted by E.D and confirmed by T.M. Stages Two to Four were informed by the inclusion 
and exclusion criteria (Table 1). Stage Two involved a screening process in which two 
authors (T.M. and N.M.) screened the literature titles and abstracts for inclusion into the next 
stage. Stage Three involved two authors (T.M., P.K.) examining the full text articles, 
followed by a quality evaluation (Stage Four) conducted by three reviewers (T.M., P.K., 
S.C.) based on a revised Newcastle-Ottawa Quality Assessment Scale [28] (refer to 
supplementary material). Finally, data was synthesized (Stage Five) using a narrative 
approach by S.C and T.M. and then reviewed by N.M., P.C. and P.K.  
 
Data sources and searches (Stage One) 
 To capture as many relevant citations as possible, a wide range of psychological, 
health, medical, and cross-disciplinary databases were searched to identify a broad range of 
literature examining the relationship between rheumatoid arthritis and cognitive function. 
These databases included: PsycINFO, PsycARTICLES, Psychology and Behavioral Sciences 
Collection, ProQuest Psychology Journals, PubMed, CINAHL Plus, Informit (health 
collection), ScienceDirect, Embase, Scopus, Web of Science, Cochrane Library, Alexander 
Street Press, National Technical Information Service, The Database of Abstracts of Reviews 
of Effects, and BIOSIS Previews. The search was limited to all literature related to the area of 
study, originally over the 20 years period January 1994 and December 2014 with update 
searches in 2015 and 2016. There was no restriction on study design or language of 
publication. Conference abstracts and poster presentations were included if there was 
sufficient details to allow appraisal of study quality. An example of an electronic search 
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strategy for PsycINFO is presented in Table 1. The full electronic search strategy is available 
online, accompanying this article.  
The searches resulted in 1,980 citations from which relevant studies were selected for 
the review based on the presence of the search terms or related terms in the title and/or 
abstract. This screening process resulted in 1,488 citations being excluded as irrelevant and 
421 duplicates were removed. A total of 71 titles were identified as relevant and were 
included in the second stage of the review.  
 
TABLE 1 ABOUT HERE 
 
Selection of Studies (Stages Two, Three and Four) 
 
 A set of pre-determined criteria for Stages Two, Three and Four is presented in Table 
2. All non-empirical research including literature reviews, book sections and letters to the 
editor, as well as animal studies and studies with participants <18 years were excluded to 
focus on empirical studies with human, adult samples. Studies meeting the inclusion criteria 
for this review were published between 1994 and 2015, related to cognitive function 
assessment and rheumatoid arthritis, involved adults aged 18 years and over, and were 
published in any language as long as an English translation was available. For any articles 
where the abstract or full manuscript could not be located, the authors of these articles were 
contacted directly, requesting access to the abstract and/or full manuscript, with follow-up 
emails sent after two weeks of non-response.  
TABLE 2 ABOUT HERE 
Literature Screening Ð abstracts (Stage Two) 
  Two researchers (T.M. and N.M.) independently reviewed the 71 abstracts and 
recorded whether they accepted or rejected the abstract based on the pre-determined inclusion 
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criteria for Stage Two (Table 2). In the case of disagreement, consensus was reached after 
discussion between the two reviewers. Four additional abstracts were identified through the 
full-text screening in Stage Three and were added to these abstracts. Subsequently, of the 75 
abstracts (refer to supplementary material), 38 were excluded for the following reasons: non-
experimental studies (n = 9), non-human (n = 1) or non-adult-specific population (n = 5), 
non-RA-specific population (n = 3), no indication of cognitive function assessment (n = 1), 
grey literature only (n = 19).  
Literature Screening Ð full-text (Stage Three) 
 Whilst grey literature such as poster presentations and conference abstracts had been 
included in Stage Two screening, once the authors confirmed that such articles had no full 
text (n = 2), they were excluded (at the commencement of Stage Three, prior to full text 
screening). Of the 35 abstracts (refer to supplementary material) that progressed to the full-
text stage, only 15 were retained. Four papers were in languages other than English and only 
one of those had an official English translation version. The full papers were reviewed by two 
authors (T.M. and P.K.) for inclusion, based on the inclusion criteria in Table 2, including: 
the use of standardized, administered cognitive function assessment, sufficient demographic 
and clinical details on RA sample, and sufficient results details. The reference lists of the 35 
papers were also reviewed and this identified a further four studies that met Stages One and 
Two inclusion criteria (as detailed above). Of the 36 full-text papers, 21 were removed from 
further consideration due to: lack of standardized cognitive function assessment (n = 8), 
duplication (more than one publication on the same dataset) (n = 6), and insufficient sample 
or results details (n = 7). The data from each individual study was then extracted and 
presented according the following items: demographics and clinical profile, study location, 
design and methodology, cognitive function assessment tools and cognitive impairment rates 
and types. Authors were contacted for clarification where information was missing.  
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Methodological Quality (Stage Four) 
The 15 studies were then evaluated using a modified version of the Newcastle-Ottawa 
Evaluation Scale (NOS) [28] (refer to supplementary material) by three authors (T.M., K.P., 
& S.C.). The NOS is a scale developed to assess the design quality of non-randomized studies 
when reporting the results of meta-analyses and systematic reviews. The scale uses a 'star 
system' with each study appraised on three criteria: the selection of the study groups; the 
comparability of the groups, and ascertaining the outcome or exposure of interest for cohort 
or case-control studies respectively [28] and provides a score between 0-8. This evaluation 
scale provides an opportunity to identify risk of bias at the study design level that is then 
further examined at the data synthesis stage. Discrepancies across evaluations were resolved 
with discussion by the three authors.  
Data synthesis (Stage Five) 
 Given the range of study designs, participant groups and assessment tools used across 
studies, and the overall small sample sizes, narrative review was determined to be the best 
option for summarizing the results. At this stage a risk of bias across studies was considered 
in relation to the studiesÕ data management and quality of reporting of results. As a part of the 
data synthesis, studies were profiled and synthesized in terms of the number of cognitive 
domains they examined, data management and reporting, and consideration of confounding 
variables. In addition, effect sizes were calculated where possible and summed together to 
provide comparisons between RA and control and other clinical groups.  
Results 
Selection of studies 
 The full selection process, detailed in the methods section, is summarized in Figure 1. 
 
FIGURE ONE ABOUT HERE 
 
 
!!
Methodological quality 
 The 15 studies were evaluated on the basis of sample selection, design and exposure. 
They ranged in total scores from 3.5 to 8 (possible range 0 Ð 8). The scores across the seven 
categories are presented in Table 3.  
 
TABLE 3 ABOUT HERE  
 
Study Characteristics  
 Fifteen studies reported on 749 participants with RA (Table 4). Sample sizes across 
studies ranged from 13 to 157 participants, with only three studies (Table 3: Studies #23, 29, 
& 30) with more than 100 participants. All but one study [31; test-retest 24 hours apart], were 
cross-sectional. Five studies [23, 29, 30, 31, 32] only included RA populations; four studies 
[33, 34, 35, 36] compared RA with control; and six studies included three [37, 38, 39, 40, 41) 
or four [42] comparison groups (RA, FM, SLE, MSD, SS and control). The majority of 
studies were conducted in the USA [23, 29, 30, 40] followed by Brazil [33, 35, 39] and 
Turkey [37, 38, 41] with the remaining studies being from Italy [32], Canada [42], Egypt 
[34], Australia [31] and Serbia [36]. 
Participants Characteristics 
 The majority (59% to 100%) of participants in the studies were female; the mean age 
ranged from 37.2 to 62.9 years (SD = 2.0 -13.5). Education levels ranged from mean 1.8 to 
15.1 years across 10 studies with two not having provided details [34, 36] and three having 
provided only prevalence rates (over 8 years: #23; under 12 years: #31, 30).  
Cognitive Impairment Prevalence 
 Of the 15 studies, three [30, 31, 33] stated the prevalence of cognitive impairment 
(30%, 0%, 31% respectively), while some only reported reduced scores [34, 40] or 
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impairment rates across individual tests [32] or combined groupsÕ rates [42] (Table 4). The 
remaining studies [23, 29, 35, 36, 37, 38, 39, 41] did not report impairment rates. 
 
TABLE 4 ABOUT HERE 
 
Cognitive Domains Measured 
 Cognitive tests were grouped across six cognitive domains [43] (refer to 
supplementary material).  Cognitive domains listed for each study are reported in Table 4. 
Across the 15 studies, four [35, 36, 37, 42] measured only one domain; two [29, 31] 
measured two domains; one measured three domains [23]; three [30 34, 39] measured four 
domains; and five [32, 33, 38, 40, 41] measured five domains. The most commonly measured 
domains were memory (13 studies) followed by judgment/problem solving (10 studies), 
attention/concentration (nine studies), and verbal function and visual-spatial organization 
(eight studies each), while orientation was not measured by any of the studies. 
Cognitive Impairment Effect Sizes Analyses  
 Cognitive impairment was further examined in terms of CohenÕs d analyses. Of 15 
studies, eight included sufficient data to calculate standardized mean difference between RA 
and other clinical and control groups. These effect sizes were calculated across all available 
neuropsychological measures (refer to supplementary material) then totaled for each domain 
and group (RA, Control, other Clinical Groups) (Table 5). Effect sizes are broadly classified 
into small, medium and large indicators of standardized differences [44]. These may be 
interpreted as not noticeable (small), noticeable (medium) and clinically significant (large) 
[45].  
 Large median CohenÕs d effect sizes were noted across three (Attention, Memory, 
Verbal Function) out of five domains between RA and Control. Similarly large effect sizes 
were noted in comparison between RA and non-CNS-SLE (although the two groups were not 
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aged matched, i.e. #39, 42) on one (Judgment) of the four domains as measured by CohenÕs d 
and in a medium range for the other three domains. RA was outperformed by FMS (medium 
d) on Attention and MSc (small/marginal) but performed better than SS on three out of four 
domains (small to large d). All clinical groups across studies performed more poorly than the 
control group. Some groups were not age or education matched and, other than RA (n = 284) 
and Control (n = 180), their sample sizes were small (n = 20 to 33). 
 
TABLE 5 ABOUT HERE 
 
Confounding variables: Demographics 
 The majority of studies controlled for age, gender and education. Mean (SD) age for 
RA group ranged from 37.2 (3.2) to 62.9 (10.9). Some of those studies [23, 32, 39, 31] found 
age, and others found education [30, 41] to be associated with cognitive function. Younger 
and more educated participants performed better across some of the cognitive domains. 
Education ranged from mean of 1.84 to 15.11 with half of the studies in the range of 5-9 
years of education. Some groups were not age or education matched [39, 42] and there was 
an overall pattern of the RA group being older than the control or other clinical groups [35, 
39, 40, 41, 42]. 
Confounding variables: Clinical 
 The inclusion, measurement, and severity of clinical variables varied considerably 
across studies. The following variables were found to be associated with cognitive function: 
pain [23, 29, 31, 36, 38], disease activity [32, 33], fatigue [37], medication 
(prednisone/steroids, MTX) [40, 31, 30], biomarkers (IL-6, B and T cells) [34, 35, 40], and 
CVD risk factors [30]. A range of assessment tools was used across studies, prohibiting 
systematic comparison of clinical profile across samples. 
!!
Confounding variables: Psychological 
 Only two studies found depression (somatic symptoms) [40] and depression and 
anxiety [36] to relate to cognitive function. Some excluded participants based on their 
depression scores [32] others either did not include a depression measure [39] or did not 
report their scores [41]. The most commonly used depression scale was the Beck Depression 
Inventory (BDI) [32, 33, 34, 35, 36, 41] followed by the!Hospital Anxiety and Depression 
Scale (HADS) [33, 37, 42]. Some studies used more than one measure (38: Diagnostic and 
Statistical Manual of Mental Disorders- Fourth Edition (DSM-IV) & overall well-being; 23: 
Center for Epidemiologic Studies Depression Scale (CES-D) & Multiple Affect Adjective 
Checklist-Revised (MAACL-R) = composite; 34: DSM-IV, BDI & Mini International 
Neuropsychiatric Interview (MINI); 35: BDI & Mini Mental State Examination (MMSE)) 
others used Arthritis Impact Measurement Scales (AIMS) [29], MMSE [39], and MINI [30] 
only. Given these measures and reporting differences, no comparison analyses of depression 
could be undertaken. 
Biases at individual study and systematic review levels  
 The following potential biases were apparent across the studies: small sample sizes; 
lack of descriptive data; insufficient details about the skills/qualifications of test 
administrators; limitations in study design and appropriate analyses adjustments, narrow 
range of variables (demographic, clinical and neuropsychological) and use of convenient 
sampling.  
 Statistical analyses across studies were limited to effect size calculations for eight out 
of 15 studies and totaling of scores based on different measures of included domains. No 
other statistical analyses were possible based on the available data. The effect sizes should be 
interpreted cautiously as no adjustment was made for demographic, clinical and 
psychological differences across those studies. 
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 According to the modified Newcastle-Ottawa Evaluation Scale (NOS) [28] the scores 
ranged from 3 to 7.5 out of 8 points, with an average of 5.3. The studies included participants 
with confirmed RA diagnosis, were age if not gender representative, and mostly matched on 
age via norms or control group. However a number of the studies failed to control for clinical 
or psychological variables in relation to cognitive function, were limited in the range of 
domains assessed (seven of 15 studies measured only one or two cognitive domains), and less 
than half provide impairment rates, scores and adequate findings explanations. 
 
Discussion 
 The aim of this systematic review was to ascertain the levels of cognitive impairment 
in RA. According to the 15 studies that met the inclusion criteria, individuals with RA either 
perform more poorly at a range of cognitive assessment tasks than healthy controls, or 
perform at a level below age-related norms. The prevalence of cognitive impairment, 
however, could not be determined as only three studies included that information. The 
presence of cognitive impairment or at least poorer cognitive function varied across studies in 
terms of the domains. However, effect size calculations conducted on eight of the studies 
indicated clinically significant differences in cognitive function in RA compared to controls 
without RA. Those findings, notwithstanding methodological limitations, are significant and 
warrant further examination. Given the level of cognitive impairment identified in these 
studies, it may be necessary to assess and monitor cognitive function over time as part of the 
overall management of RA 
 Different explanations have been proposed for the apparent CI in RA. Given that 
other clinical groups included across the studies have also performed more poorly than 
healthy controls, this suggests that CI may not be specific to a particular condition but present 
across number of chronic, painful, inflammatory or autoimmune conditions. A number of 
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mechanisms may be involved in CI in RA including: chronic inflammation, medication 
(especially corticosteroids, methotrexate) and premature!immunosenescence [35]. Findings 
from studies that have included neuroimaging data suggest brain involvement with structural 
and functional changes that may not clinically manifest but could be associated with 
rheumatoid vasculitis, chronic inflammation, demyelination [32, 34, 35]. Further, immune 
activities such as alternations in!dehydroepiandrosterone (DHEA) metabolism also appear to 
be associated with CI particularly in relation to attention and learning, even when controlling 
for depression and in sample with mild disease activity [35, 40]. Medication may also impact 
on CI temporarily at single and accumulative dose levels [22, 23, 30, 31]. Finally, pain, 
fatigue, poor sleep and depression may be attentional distractions, and in turn impact on 
cognition [23, 33, 37]. How these biological, clinical and psychological variables interact in 
the development of CI is yet to be determined. 
 This review, however, identified a number of limitations across the studies that should 
be taken into consideration. These include the following: (1) small sample size across studies 
and in overall analysis of findings; (2) poor reporting of study details and CI in particular; (3) 
a lack of generalizability with predominantly female samples; (4) a limited range of cognitive 
domains inclusion; (5) lack of management of confounding variables (i.e. medication); (6) 
varied definitions of CI (i.e., number of tests with performance below norm/total number of 
tests); and (7) the use of established RA samples only. At the systematic review level, notable 
limitations include: (1) evaluation being limited to qualitative, narrative approach; and (2) 
overall effect size analyses conducted without controlling for confounding variables.  
 To our knowledge this is the first systematic review of CI in RA and its strength is in 
inclusion of only the studies that have used standardized neurocognitive assessment tools. 
Over half of these studies also included control groups Ð both healthy controls and other 
clinical groups to compare to RA. These are methodological strengths and while the findings 
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are mixed they provide a platform for further research with larger samples and stronger study 
designs. Such research should examine cognitive impairment at diagnosis and at regular 
intervals including flare-ups and medication changes; conduct comprehensive comparisons 
across age, gender, disease duration, and disease severity; and identify factors that may differ 
between RA patients with and without CI. The potential impact of CI, even at a sub-clinical 
level, is considerable. In relation to RA management, it is essential that future research seek 
to comprehensively assess CI levels, examine its etiology, and determine preventative and 
treatment measures.  
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Figure 1. Flowchart: Literature Search and Studies Selection. 
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Table 1. 
Electronic search strategy for PsycINFO database 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. 
Inclusion and exclusion criteria for selection of the articles  
Database 
 
Search # Search strategy Search 
Results 
PsychINFO 
(January 1994- 
December 
2015) 
1 Rheumat* Arthriti* AND Cognitive 
function*.ab 
17 
2 Rheumat* Arthriti* AND Cognitive 
Impair*.ab 
17 
3 Rheumat* Arthriti* AND Executive 
function*.ab 
5 
 4 Rheumat* Arthriti* AND Executive 
function* AND memory.ab 
3 
 5 Rheumat* Arthriti* AND Cognitive 
Impair* AND Memory.ab 
6 
 6 Rheumat* Arthriti* AND Cognitive 
function* AND Memory.ab 
4 
 7 Rheumat* Arthriti* AND Cognitive 
decline.ab 
4 
 8 Rheumat* Arthriti* AND Cognitive 
dysfunction.ab 
7 
 9 Rheumat* Arthriti* AND neurological 
function*.ab 
1 
 10 Rheumat* Arthriti* AND neurological 
impair*.ab 
3 
 11 Rheumat* Arthriti* AND neurological 
function* AND attention.ab 
0 
 12 Rheumat* Arthriti* AND neurological 
function* AND memory.ab 
0 
 13 Rheumat* Arthriti* AND neurological 
impair* AND attention.ab 
1 
 14 Rheumat* Arthriti* AND neurological 
impair* AND memory.ab 
1 
Total number of articles 
 
69 
Total number of duplicates 27 
 
Potentially relevant (after screening titles and abstracts) 
 
19 
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Title and Abstract Inclusion Criteria  
TITLE: includes words:  
(1) Ôrheumatoid arthritisÕ or some variation of it (i.e. rheumatic disorders)  
AND/OR  
(2) Ôcognitive functionÕ or some variation of it (i.e. neurocognitive function, cognitive 
dysfunction)   
ABSTRACT: indicates: 
(1) Empirical study 
(2) Human sample,  
(3) Adult sample,  
(4) Rheumatoid arthritis sample  
(5) Cognitive function 
(6) Grey literature included if sufficiently detailed to appraise study quality 
(7) English version available  
Full article Inclusion Criteria  
(1) Sufficient demographic and clinical details on RA sample  
(2) Use of standardized, objective cognitive tests  
Full article Exclusion Criteria  
(1) Use of self- report/modified/computerized and/or neurological tests only  
(2) Duplicate data   
(3) Insufficient results details (i.e. cognitive function in RA results) 
(4) No objective measure of cognitive function 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. 
 
Modified Newcastle-Ottawa Quality Assessment of 15 Studies  
 
Study
ref 
Selection  
3 points 
Comparability 
2 points 
Exposure 
3 points 
Total 
8 
points    S1 
1  
S2 
1  
S3 
1  
C1 
(a) !  
C2 
½ 
C3 
½ 
E1 
1½ 
E2  
1½ 
!!
(b) !    
Abeare et 
al. (2010)
29 
1 1 0 0 0 0 ! ! 3.0 
 Akdogan et 
al. (2013)
37 
1 ! 0 1 ! ! 0 ! 4.0 
Appenzeller 
et al. 
(2004)
33 
1 1 ! ! 0 0 1 ! 1 ! 6.0 
Bartolini et 
al. (2002)
32 
1 1 1 1 !  ! 
 
1 ! 1 7.5 
Bilgici et al. 
(2014)
38 
1 ! ! ! 0 0 1 ! ! 4.5 
Brown et 
al. (2002)
23 
1 1 0 ! ! ! 1 ! 5.0 
de Melo et 
al. (2012)
39 
1 ! 1 0 0 0 1 1 4.5 
Dick et al. 
(2002)
42 
1 1 ! ! 0 0 0 1 4.0 
Hamed et 
al. (2012)
34 
1 ! 1 1 ! 0 1 1 6.0 
Kozora et 
al. (2001)
40 
1 !  1 1 ! !   1 ! 1  7.0 
Meade et 
al. (2013)
31 
1 1  
 
1 0 !  
 
0 ! 
 
1!   5.5 
Petersen et 
al. (2014)
35 
1 1 1 1 ! ! 0 1 6.0 
Shin et al. 
(2013)
30 
1 1  1 1  ! !   1 !  
 
1 7.5 
Tomasević 
et al. 
(2011)
36 
1 1 1 1 0 0 0 ! 4.5 
Yilmaz et 
al. (2012)
41 
1 1 1 1 ! ! 1 ! ! 7.0 
Note: S1= Selection criterion 1; S2= Selection criterion 2; S3= Selection criterion 3; C1= Comparability 
criterion 1; C2= Comparability criterion 2; C3= Comparability criterion 3; E1= Exposure criterion 1; E2= 
Exposure criterion 2.
